Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG (mIBG)

This study has been completed.
National Cancer Institute (NCI)
Molecular Insights Pharmaceuticals
Information provided by (Responsible Party):
Bennett Chin, Duke University Medical Center Identifier:
First received: November 7, 2012
Last updated: November 20, 2012
Last verified: November 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2011
  Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Chin BB, Grasfeder L, Femia F, Hillier S, Petry N, Armor T, Stubbs J, Stabin M, Babich J, Kronauge J. Phase 1 clinical trial results for high specific activity Ultratrace Iobenguane I 123. J Nucl Med. 2012;53:1516.

Publications automatically indexed to this study by Identifier (NCT Number):